Gwang-Cheol Park
Vorstandsvorsitzender bei Premierbio Co., Ltd.
Profil
Gwang-Cheol Park is currently the Chief Executive Officer at Premierbio Co., Ltd.
Prior to this, he was the Chairman & Co-Chief Executive Officer at DSK Co., Ltd.
and an Independent Director at KB Securities Co., Ltd.
He received his undergraduate, graduate, and doctorate degrees from Konkuk University.
Aktive Positionen von Gwang-Cheol Park
| Unternehmen | Position | Beginn |
|---|---|---|
Premierbio Co., Ltd.
 Premierbio Co., Ltd. Pharmaceuticals: OtherHealth Technology Premierbio Co., Ltd. is engaged in developing Protoxin. It offers development and supply of Botulinum type A Toxin. The company was founded on September 25, 2015 and is headquartered in Anseong, South Korea. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Gwang-Cheol Park
| Unternehmen | Position | Ende |
|---|---|---|
| DSK CO., LTD. | Vorstandsvorsitzender | - |
| HYUNDAI SECURITIES CO LTD | Direktor/Vorstandsmitglied | - |
Ausbildung von Gwang-Cheol Park
| Konkuk University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| DSK CO., LTD. | Electronic Technology |
| Private Unternehmen | 2 |
|---|---|
KB Securities Co., Ltd
 KB Securities Co., Ltd Investment ManagersFinance KB Securities Co., Ltd (KB Securities) is a private equity subsidiary of KB Financial Group, Inc. founded in 1962. The firm is headquartered in Seoul, South Korea. | Finance |
Premierbio Co., Ltd.
Premierbio Co., Ltd. Pharmaceuticals: OtherHealth Technology Premierbio Co., Ltd. is engaged in developing Protoxin. It offers development and supply of Botulinum type A Toxin. The company was founded on September 25, 2015 and is headquartered in Anseong, South Korea. | Health Technology |
